Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 516

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on pathophysiology and treatment of acute GVHD

Robert Zeiser

Blood (2020) 136 (4): 375–376.

https://doi.org/10.1182/blood.2019004271

Published: 2020

Journal Articles

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Michael F. Guerrera, MD, Gita Massey, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 2396.

https://doi.org/10.1182/blood-2019-126944

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Veit Bücklein, MD, Alexandra Stein, Benjamin Tast, PhD, Thomas Koehnke, MD, Karsten Spiekermann, MD, Francis Lacombe, MD PhD, Marion Subklewe, MD

Blood (2019) 134 (Supplement_1): 4656.

https://doi.org/10.1182/blood-2019-129866

Published: 2019

Journal Articles

Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study

Janet L. Kwiatkowski, MD MSCE, Alexis A. Thompson, MD MPH, John E.J. Rasko, MBBS, PhD, Suradej Hongeng, MD, Gary J. Schiller, MD, Usanarat Anurathapan, MD, Marina Cavazzana, MD PhD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Manfred Schmidt, PhD, Morris Kletzel, MD MBA, Elliott P. Vichinsky, MD, Briana Deary, Ying Chen, PhD, Alexandria Petrusich, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 4628.

https://doi.org/10.1182/blood-2019-125807

Published: 2019

Journal Articles

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Steven Pipe, MD, Michael Becka, Elke Detering, Konstantina Vanevski, Toshko Lissitchkov

Blood (2019) 134 (Supplement_1): 4630.

https://doi.org/10.1182/blood-2019-125764

Published: 2019

Journal Articles

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Pietro Merli, MD, Annalisa Ruggeri, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Giulia Ceglie, MD, Katiana Gruppioni, MPH, Sanjeev Kommera, MS, Jenfue Maa, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 969.

https://doi.org/10.1182/blood-2019-123440

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Pietro Merli, MD, Daria Pagliara, MD PhD, Mattia Algeri, MD, Federica Galaverna, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Mauro Montanari, MD, Giovanna Leone, MD, Stefania Gaspari, MD, Michele Massa, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Simone Biagini, MSc, Marco Becilli, MD, Elia Girolami, MSc, Roberto Carta, MD, Annalisa Ruggeri, MD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 799.

https://doi.org/10.1182/blood-2019-128416

Published: 2019

Journal Articles

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, MD, Anthony Stein, MD, Roland B. Walter, MD PhD MS, Ravi Bhatia, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, David Ritchie, MD PhD, Veit Bücklein, MD, Pankit Vachhani, MD, Tian Dai, PhD, Antreas Hindoyan, PhD, Suresh Agarwal, PhD, Abraham Anderson, Sophia Khaldoyanidi, MD PhD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 833.

https://doi.org/10.1182/blood-2019-127977

Published: 2019

Journal Articles

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Francesca Del Bufalo, MD, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Ignazio Caruana, PhD, Matilde Sinibaldi, PhD, Luciana Vinti, MD, Pietro Merli, MD, Mattia Algeri, MD, Annalisa Ruggeri, MD, Federica Galaverna, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Giovanna Leone, MD, Valentina Bertaina, PhD, Franca Fassio, PhD, Monica Gunetti, PhD, Stefano Iacovelli, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 1341.

https://doi.org/10.1182/blood-2019-129821

Published: 2019

Journal Articles

Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1499.

https://doi.org/10.1182/blood-2019-128516

Published: 2019

Journal Articles

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

Xiaoxian Zhao, PhD, Bartlomiej Przychodzen, Juraj Bodo, PhD, Lisa Durkin, Daniel Lindner, MD PhD, Neetha Parameswaran, PhD, Michael Clemente, MS, Sarah L. Ondrejka, DO, Jaroslaw P. Maciejewski, MD PhD, Deepa Jagadeesh, MDMPH, Eric D. Hsi, MD

Blood (2019) 134 (Supplement_1): 1572.

https://doi.org/10.1182/blood-2019-129131

Published: 2019

Journal Articles

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Myrna Nahas, MD, Dina Stroopinsky, PhD, Marzia Capelletti, PhD MBBS, Jacalyn Rosenblatt, MD, Shira Orr, PhD, Haider Ghiasuddin, Adam Morin, Jessica Liegel, MD, Donald Kufe, MD, David E. Avigan, MD

Blood (2019) 134 (Supplement_1): 1386.

https://doi.org/10.1182/blood-2019-122438

Published: 2019

Journal Articles

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Pier Edoardo Rovatti, MD, Laura Zito, MSc, Eleonora Draghi, MSc, Monika Herrmann, PhD, Anetta Marcinek, MSc, Bettina Brauchle, MSc, Cesare Covino, MSc, Mattia Di Bono, MSc, Matteo Giovanni Carrabba, MD, Massimo Bernardi, MD, Karl-Peter Hopfner, PhD, Cristina Toffalori, PhD, Fabio Ciceri, MD, Marion Subklewe, MD, Luca Vago, MD PhD

Blood (2019) 134 (Supplement_1): 513.

https://doi.org/10.1182/blood-2019-126641

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 460.

https://doi.org/10.1182/blood-2019-121870

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Introduction to a review series on pathophysiology and treatment of acute GVHD

Peri-Procedural Management and Outcomes of Patients with Hemophilia on Emicizumab Prophylaxis

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Flowsom: An R-Based Evaluation Strategy for Flow Cytometry-Based Measurable Residual Disease (MRD) Diagnostics in Acute Myeloid Leukemia (AML)

Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study

First-in-human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A

Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Transfusion-Dependent β-Thalassemia Treated at the Bambino Gesù Children's Hospital, Rome, Italy

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Long-Term Outcome of Children with Acute Leukemia (AL) Given Alphabeta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE ® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Higher Stability of Mutant mRNA As Compared to Wild-Type mRNA in Diffuse Large B-Cell Lymphoma

Angioimmunoblastic T-Cell Lymphoma: Molecular Characterization of Clonal T and B-Cells and a Patient Derived Xenograft Model of Coexisting T and B-Cell Proliferations

CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model

Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Immune Landscapes Predict Chemotherapy Resistance and Anti-Leukemic Activity of Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only